MedTrace Logo

Signaling Mechanisms and Vascular Function in Diabetes Mellitus

NCT00761852 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2008-09-30

No results posted yet for this study

Summary

Ruboxistaurin is being tested to see if it is effective in treating certain diabetic complications, such as diseases of the blood vessels.

Conditions

Interventions

DRUG

Ruboxistaurin

32 mg daily for 2 weeks

DRUG

Placebo

1 tab po QD for 2 weeks

Sponsors & Collaborators

Principal Investigators

  • Mark A Creager, MD · Brigham and Women's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1999-05-31
Primary Completion
2007-10-31
Completion
2007-10-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00761852 on ClinicalTrials.gov